A new trading day began on Tuesday, with KalVista Pharmaceuticals Inc (NASDAQ: KALV) stock price down -3.34% from the previous day of trading, before settling in for the closing price of $11.54. KALV’s price has ranged from $7.30 to $15.50 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -24.26% over the past five years. Meanwhile, its annual earnings per share averaged -3.28%. With a float of $38.56 million, this company’s outstanding shares have now reached $49.49 million.
Let’s look at the performance matrix of the company that is accounted for 150 employees. In terms of profitability, gross margin is 63.27%, operating margin of -15043.2%, and the pretax margin is -14230.76%.
KalVista Pharmaceuticals Inc (KALV) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of KalVista Pharmaceuticals Inc is 22.44%, while institutional ownership is 89.05%. The most recent insider transaction that took place on Mar 07 ’25, was worth 79,828. In this transaction CHIEF EXECUTIVE OFFICER of this company sold 6,669 shares at a rate of $11.97, taking the stock ownership to the 287,811 shares. Before that another transaction happened on Feb 24 ’25, when Company’s CHIEF MEDICAL OFFICER sold 2,394 for $10.02, making the entire transaction worth $23,988. This insider now owns 102,940 shares in total.
KalVista Pharmaceuticals Inc (KALV) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.95 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -3.28% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 20.85% during the next five years compared to -20.06% drop over the previous five years of trading.
KalVista Pharmaceuticals Inc (NASDAQ: KALV) Trading Performance Indicators
Here are KalVista Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 10.44.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.73, a number that is poised to hit -0.85 in the next quarter and is forecasted to reach -2.97 in one year’s time.
Technical Analysis of KalVista Pharmaceuticals Inc (KALV)
KalVista Pharmaceuticals Inc (NASDAQ: KALV) saw its 5-day average volume 0.5 million, a positive change from its year-to-date volume of 0.46 million. As of the previous 9 days, the stock’s Stochastic %D was 23.60%. Additionally, its Average True Range was 0.64.
During the past 100 days, KalVista Pharmaceuticals Inc’s (KALV) raw stochastic average was set at 68.84%, which indicates a significant increase from 7.85% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 36.19% in the past 14 days, which was lower than the 53.59% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.66, while its 200-day Moving Average is $11.10. Nevertheless, the first resistance level for the watch stands at $11.62 in the near term. At $12.08, the stock is likely to face the second major resistance level. The third major resistance level sits at $12.38. If the price goes on to break the first support level at $10.86, it is likely to go to the next support level at $10.56. The third support level lies at $10.10 if the price breaches the second support level.
KalVista Pharmaceuticals Inc (NASDAQ: KALV) Key Stats
With a market capitalization of 554.58 million, the company has a total of 49,716K Shares Outstanding. Currently, annual sales are 0 K while annual income is -126,640 K. The company’s previous quarter sales were 0 K while its latest quarter income was -48,510 K.
